Related Experiment Video
Updated: Dec 20, 2025
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
Published on: January 27, 2023
A Novel Multiplex Based Platform for Osteoarthritis Drug Candidate Evaluation
Michael Neidlin1, Efthymia Chantzi2, George Macheras3
1Department of Mechanical Engineering, National Technical University of Athens, Heroon Polytechniou 9, 15780, Zografou, Greece.
Abstract:
Osteoarthritis (OA) is characterized by irreversible cartilage degradation with very limited therapeutic interventions. Drug candidates targeted at prototypic players had limited success until now and systems based approaches might be necessary. Consequently, drug evaluation platforms should consider the biological complexity looking beyond well-known contributors of OA. In this study an ex vivo model of cartilage degradation, combined with measuring releases of 27 proteins, was utilized to study 9 drug candidates. After an initial single drug evaluation step the 3 most promising compounds were selected and employed in an exhaustive combinatorial experiment. The resulting most and least promising treatment candidates were selected and validated in an independent study. This included estimation of mechanical properties via finite element modelling (FEM) and quantification of cartilage degradation as glycosaminoglycan (GAG) release. The most promising candidate showed increase of Young's modulus, decrease of hydraulic permeability and decrease of GAG release. The least promising candidate exhibited the opposite behaviour. The study shows the potential of a novel drug evaluation platform in identifying treatments that might reduce cartilage degradation. It also demonstrates the promise of exhaustive combination experiments and a connection between chondrocyte responses at the molecular level with changes of biomechanical properties at the tissue level.
Insights
This study developed a new platform to test osteoarthritis drugs, identifying a promising treatment that improved cartilage biomechanics and reduced degradation. The approach connects molecular responses to tissue-level changes for better drug evaluation.
Area of Science:
- Biomedical Engineering
- Pharmacology
- Orthopedics
Background:
- Osteoarthritis (OA) involves irreversible cartilage degradation with limited therapeutic options.
- Current drug development often overlooks OA's biological complexity.
- Systems-based approaches are needed for effective OA drug discovery.
Purpose of the Study:
- To evaluate drug candidates for osteoarthritis using a novel ex vivo cartilage degradation model.
- To identify effective drug combinations through exhaustive combinatorial experiments.
- To link molecular-level chondrocyte responses to tissue-level biomechanical changes.
Main Methods:
- Utilized an ex vivo cartilage degradation model measuring 27 protein releases.
- Screened 9 drug candidates, followed by combinatorial testing of the top 3.
- Validated promising candidates using finite element modeling (FEM) and glycosaminoglycan (GAG) release quantification.
Main Results:
- Identified a top-performing drug candidate that enhanced Young's modulus and reduced hydraulic permeability and GAG release.
- The least promising candidate showed opposite effects on these properties.
- Demonstrated a correlation between molecular responses and biomechanical property changes.
Conclusions:
- The novel drug evaluation platform shows potential for identifying effective OA treatments.
- Exhaustive combination experiments are valuable for optimizing therapeutic strategies.
- Connecting molecular and biomechanical data provides a comprehensive understanding of treatment efficacy.
Related Concept Videos
01:26Drug Discovery: Overview
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
01:28Preclinical Development: Overview